These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11844901)

  • 1. Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses?
    Dressler D; Münchau A; Bhatia KP; Quinn NP; Bigalke H
    Eur Neurol; 2002; 47(2):118-21. PubMed ID: 11844901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-induced failure of botulinum toxin type B therapy in de novo patients.
    Dressler D; Bigalke H
    Eur Neurol; 2004; 52(3):132-5. PubMed ID: 15479980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure.
    Dressler D; Bigalke H
    J Neurol; 2005 Aug; 252(8):904-7. PubMed ID: 15761672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.
    Dressler D
    Mov Disord; 2004 Mar; 19 Suppl 8():S92-S100. PubMed ID: 15027060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electromyographic quantification of the paralysing effect of botulinum toxin in the sternocleidomastoid muscle.
    Dressler D; Rothwell JC
    Eur Neurol; 2000; 43(1):13-6. PubMed ID: 10798896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse diaphragm assay for detection of antibodies against botulinum toxin type B.
    Dressler D; Lange M; Bigalke H
    Mov Disord; 2005 Dec; 20(12):1617-9. PubMed ID: 16078216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin antibody titres: measurement, interpretation, and practical recommendations.
    Dressler D; Rothwell JC; Bhatia K; Kopp B; Bigalke H; Adib Saberi F
    J Neurol; 2023 Mar; 270(3):1524-1530. PubMed ID: 36434127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sternocleidomastoid test: an in vivo assay to investigate botulinum toxin antibody formation in humans.
    Dressler D; Bigalke H; Rothwell JC
    J Neurol; 2000 Aug; 247(8):630-2. PubMed ID: 11041331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
    Dressler D; Bigalke H; Benecke R
    J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical relevance of botulinum toxin antibodies].
    Dressler D
    Nervenarzt; 2008 Jun; 79 Suppl 1():36-40. PubMed ID: 18927965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity.
    Dressler D; Pan L; Adib Saberi F
    J Neural Transm (Vienna); 2018 Oct; 125(10):1481-1486. PubMed ID: 30066275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of EMG interference pattern analysis in botulinum toxin treatment of torticollis: a randomised, controlled and blinded study.
    Werdelin L; Dalager T; Fuglsang-Frederiksen A; Regeur L; Karlsborg M; Korbo L; Munck O; Winge K
    Clin Neurophysiol; 2011 Nov; 122(11):2305-9. PubMed ID: 21636319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy.
    Dressler D; Bigalke H
    Mov Disord; 2002 Jan; 17(1):170-3. PubMed ID: 11835457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy.
    Dressler D
    Eur Neurol; 2002; 48(1):26-9. PubMed ID: 12138306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A.
    Houser MK; Sheean GL; Lees AJ
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):577-80. PubMed ID: 9598669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M; Wissel J; Müller J; Poewe W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity.
    Müller K; Mix E; Adib Saberi F; Dressler D; Benecke R
    J Neural Transm (Vienna); 2009 May; 116(5):579-85. PubMed ID: 19352590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing botulinum toxin type a antibodies: clinical observations in patients with cervical dystonia.
    Rollnik JD; Wohlfarth K; Dengler R; Bigalke H
    Neurol Clin Neurophysiol; 2001; 2001(3):2-4. PubMed ID: 12396862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis.
    Dressler D; Benecke R
    Eur Neurol; 2003; 49(1):34-8. PubMed ID: 12464716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.
    Sheean GL; Lees AJ
    J Neurol Neurosurg Psychiatry; 1995 Dec; 59(6):601-7. PubMed ID: 7500097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.